121 related articles for article (PubMed ID: 3040287)
1. Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer.
Milroy R; Cummings J; Kaye SB; Banham SW
Cancer Chemother Pharmacol; 1987; 20(1):75-7. PubMed ID: 3040287
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Joss RA; Obrecht JP; Alberto P; Siegenthaler P; VanHelvoirt A; Cavalli F
Cancer Treat Rep; 1984 Mar; 68(3):563-4. PubMed ID: 6322990
[No Abstract] [Full Text] [Related]
3. Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
Hochster HS; Green MD; Blum RH; Wernz JC; Speyer JL; Muggia FM
Invest New Drugs; 1986; 4(3):275-8. PubMed ID: 3469171
[TBL] [Abstract][Full Text] [Related]
4. The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Martoni A; Pacciarini MA; Pannuti F
Drugs Exp Clin Res; 1985; 11(2):127-31. PubMed ID: 3915281
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
[TBL] [Abstract][Full Text] [Related]
6. Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.
Cummings J; Milroy R; Banham SW; Kaye SB
Cancer Chemother Pharmacol; 1987; 19(4):296-300. PubMed ID: 3036387
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
Am J Clin Oncol; 1985 Oct; 8(5):377-9. PubMed ID: 3864366
[TBL] [Abstract][Full Text] [Related]
8. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
Martoni A; Pacciarini MA; Pannuti F
Eur J Cancer Clin Oncol; 1985 Jul; 21(7):803-6. PubMed ID: 3862582
[TBL] [Abstract][Full Text] [Related]
9. Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease.
Cullen MH; Smith SR; Benfield GF; Woodroffe CM
Cancer Treat Rep; 1987 Dec; 71(12):1227-30. PubMed ID: 2825991
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
11. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC).
Ardizzoni A; Pronzato P; Repetto L; De Palma M; Canobbio L; Gulisano M; Fusco V; Rosso R; Ganzina F
Cancer Invest; 1988; 6(4):409-11. PubMed ID: 2846128
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Chisesi T; Capnist G; de Dominicis E; Dini E
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
[TBL] [Abstract][Full Text] [Related]
14. 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
Bruzzone M; Chiara S; Falcone A; Graziani G; Conte PF; Rosso R
Chemioterapia; 1987 Apr; 6(2):137-9. PubMed ID: 3474080
[TBL] [Abstract][Full Text] [Related]
15. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Budman D; Sordillo P; Watson RC
Cancer Chemother Pharmacol; 1985; 14(1):79-80. PubMed ID: 3855289
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
Kavanagh JJ; Yeung KY; Savaraj N; Krakoff IH
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1187-9. PubMed ID: 3865774
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
Smith DB; Howell A
Eur J Cancer Clin Oncol; 1987 Apr; 23(4):391-4. PubMed ID: 3475204
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.
Smith DB; Margison JM; Lucas SB; Wilkinson PM; Howell A
Cancer Chemother Pharmacol; 1987; 19(2):138-42. PubMed ID: 3471367
[TBL] [Abstract][Full Text] [Related]
19. Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Wander HE; Meyer D; Schuff-Werner P; Nagel GA
Onkologie; 1986 Aug; 9(4):236-8. PubMed ID: 3531951
[No Abstract] [Full Text] [Related]
20. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
